Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions?
Nektar Therapeutics NKTR develops drug candidates based on its PEGylation and polymer conjugate technology platforms that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. […]